Cipla Ltd has priced its generic version of remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, the Indian drugmaker said on Wednesday, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
Cipla had earlier said pricing would not exceed 5,000 rupees. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch.
Cipla India business chief executive officer and executive vice president Nikhil Chopra said in an emailed statement that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000 vials within the first month.
The drug will be available through the government and hospitals only, the company said.
Sources had told Reuters that the first batch of 10,000 vials had been printed with a price of 4,000 rupees, 800 rupees below the cheapest option, launched by European competitor Mylan this week.
It was not immediately clear how many of Cipla’s vials would be required for a full treatment course. Gilead has said a patient would typically need six vials of remdesivir for a five-day course.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.